Verheyen N, et al. - Bone turnover markers were assessed in patients with primary hyperparathyroidism subsequent to eight weeks mineralocorticoid receptor (MR)-blockade with eplerenone, in a randomized, placebo-controlled trial. Findings provided first evidence that short-term MR antagonism may not impact bone turnover, at least in patients with primary hyperparathyroidism.